Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best hot stocks to buy according to analysts. On February 19, Praxis Precision Medicines reported the financial results for Q4 2025, ending 2025 with $926 million in cash & investments. Following an additional $621 million financing in January, the company’s cash runway is now expected to fund operations into 2028. While R&D expenses rose to $267.1 million for the full year due to intensified clinical activity, the company has also expanded its leadership team and Board of Directors to support its upcoming commercial launches and long-term clinical strategy.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) submitted two NDAs to the FDA for ulixacaltamide, aimed at treating essential tremor, and relutrigine, for specific pediatric epileptic encephalopathies. Both therapies have received Breakthrough Therapy Designation, with ulixacaltamide notably being the first investigational therapy to show positive Phase 3 results for essential tremor.

Praxis Precision Medicines (PRAX) Reports $926M 2025 Cash Balance, Extended Runway

The company is advancing several high-potential programs through its Cerebrum and Solidus platforms. Vormatrigine, a potent sodium-channel modulator for epilepsy, is expected to yield Phase 3 topline results in Q2 2026, while the antisense oligonucleotide elsunersen is on track for Phase 1/2 results in H1 2026. Beyond its late-stage assets, Praxis Precision Medicines intends to nominate three new development candidates by mid-2026 to address conditions such as autism spectrum disorders and intellectual disabilities, with regulatory submissions planned for the next two years.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company that develops therapies for central nervous system/CNS disorders characterized by neuronal excitation-inhibition imbalance in the US.

While we acknowledge the risk and potential of PRAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRAX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.